Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fractionation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Fractionation. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-002765-36 Sponsor Protocol Number: IEO38 Start Date*: 2014-03-23
    Sponsor Name:Istituto Europeo di Oncologia
    Full Title: SIB –IMRT using a modulated accelerated fractionation for head and neck cancer patients
    Medical condition: head and neck squamous cell carcinoma eligible for a curative treatment with radiotherapy and Cetuximab
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002129-39 Sponsor Protocol Number: XC.ROD.2017 Start Date*: 2017-08-02
    Sponsor Name:XCELL Medical Solutions
    Full Title: Phase II Clinical Trial to Know the effectiviness and safety with a a treatment based in a therapy with serical autologous white cells versus the use of Platelet Rich Plasma in patients with rotu...
    Medical condition: Patients with Rotulian Tendinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10043237 Tendon, ligament and cartilage disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004214-16 Sponsor Protocol Number: FS014 Start Date*: 2005-01-19
    Sponsor Name:Committee of Management, Common Services Agency T/A Scottish National Blood Transfusion Service
    Full Title: A randomised control clinical study to determine whether SNBTS Fibrin Sealant promotes wound healing in patients undergoing cardiac surgery.
    Medical condition: In patients undergoing cardiac surgery the saphenous leg vein is used to replace veins used in coronary artery bypass grafts (CABG) surgery.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10006894 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002340-42 Sponsor Protocol Number: SBG-2-03 Start Date*: 2008-09-16
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck can...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005475-14 Sponsor Protocol Number: 1144 Start Date*: 2005-10-17
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: INTEnsification Radiotherapy with Accelerated fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038038 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001056-19 Sponsor Protocol Number: HUPA-EC-02-2012 Start Date*: 2013-12-01
    Sponsor Name:FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS
    Full Title: ROLE OF BIOLOGICAL THERAPY IN ROTATOR CUFF TENDINOPATHY. EFFECTIVENESS OF PLASMA RICH IN GROWTH FACTOR (PRGF-ENDORET)REGARDING TO FUNCTIONAL CAPACITY AND PAIN COMPARED WITH THE CONVENTIONAL TREATME...
    Medical condition: ROTATOR CUFF TENDINOPATHY
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10039226 Rotator cuff injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005565-54 Sponsor Protocol Number: SBG-2-04 Start Date*: 2008-12-08
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck can...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006549-42 Sponsor Protocol Number: EN3285-302 Start Date*: 2008-06-11
    Sponsor Name:Endo Pharmaceuticals Inc.
    Full Title: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Subjects wi...
    Medical condition: Severe Oral Mucositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000889-36 Sponsor Protocol Number: H6Q-MC-S020 Start Date*: 2006-08-10
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer
    Medical condition: brain metastastases of non-small or small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Completed) DK (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005225-37 Sponsor Protocol Number: 16-12301 Start Date*: 2019-12-10
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patien...
    Medical condition: Stage I Non-small cell lung cancer (NSCLC) that has been treated with Stereotactic Body Radiotherapy (SBRT).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004820-37 Sponsor Protocol Number: PRGF/AF/2011 Start Date*: 2012-06-13
    Sponsor Name:Fundación FISEVI
    Full Title: Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot processed with PRGF-System tecnology in the treatment of anal fistulas in Crohn's pat...
    Medical condition: Perianal fistulas in Crohn's Disease Patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10068659 Perianal fistula LLT
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006127-38 Sponsor Protocol Number: PRGF/AF/SIN/2011 Start Date*: 2012-06-05
    Sponsor Name:Fundación FISEVI
    Full Title: Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot in processed with PRGF-system technology, in the treatment of anal fistulas in Crohn'...
    Medical condition: Perianal fistulas in Crohn's Disease Patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10002156 Anal fistula PT
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006025-73 Sponsor Protocol Number: 01-06-TL-322OPI-004 Start Date*: 2007-04-18
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Limited,
    Full Title: A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS® Pioglitazone HCl in Subjects ...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) FR (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) AT (Completed) ES (Completed) GR (Prematurely Ended) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000377-25 Sponsor Protocol Number: Debio1143-SCCHN-301 Start Date*: 2020-10-06
    Sponsor Name:Debiopharm International S.A.
    Full Title: A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients wi...
    Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) HU (Ongoing) PT (Ongoing) AT (Ongoing) BE (Ongoing) CZ (Completed) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005492-17 Sponsor Protocol Number: 01-06-TL-322OPI-002 Start Date*: 2007-01-19
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.,
    Full Title: A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCl (Actos), SYR-322 Alone or Pioglitazone HCl Alone in Subjects with Type 2 Diabetes
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) SK (Completed) EE (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-006417-32 Sponsor Protocol Number: P04889 Start Date*: 2008-02-06
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)
    Medical condition: HIV infection (R5 tropism only) with previous therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10200172 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022209-16 Sponsor Protocol Number: ICON8 Start Date*: 2011-04-08
    Sponsor Name:University College London
    Full Title: ICON8 Trials Programme ICON8: An international phase 3 randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as ...
    Medical condition: ICON8: Newly diagnosed high risk early stage (FIGO stage IC/IIA, grade 3 or clear cell histology only) or advanced stage (FIGO stage IIB-IV, all grades and all histological types) epithelial ovaria...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002192-33 Sponsor Protocol Number: TRADEhypo Start Date*: 2020-02-06
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
    Medical condition: unresectable stage III NSCLC (Non–small-cell lung cancer)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002392-33 Sponsor Protocol Number: N12HYB Start Date*: 2012-06-12
    Sponsor Name:NKI-AVL
    Full Title: Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm
    Medical condition: NSCLC stage III or inoperable stage II
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062041 Lung infiltration malignant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023779 Large cell lung cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025036 Lung adenocarcinoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10025082 Lung disorder PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025031 Lung adenocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025069 Lung carcinoma cell type unspecified stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001250 Adenosquamous cell lung cancer stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025124 Lung squamous cell carcinoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025037 Lung adenocarcinoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002315-25 Sponsor Protocol Number: TAK-475/EC303 Start Date*: 2005-12-15
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet...
    Medical condition: Treatment of patients with primary dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA